Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Molecular target structures in oncology].

K Spiekermann1, W Hiddemann

  • 1Klinische Kooperationsgruppe Leukämie, Medizinische Klinik III, Klinikum Grosshadern der Ludwig-Maximilians-Universität München und GSF-Hämatologikum, Marchioninistrasse 15, 81377, München, Germany. karsten.spiekermann@med.uni-muenchen.de

Der Internist
|July 12, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?

ESMO gastrointestinal oncology·2026
Same author

Correction: Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis.

Infection·2025
Same author

Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis.

Infection·2025
Same author

Diverse clinical manifestations of Parvovirus B19 infections during the 2024 outbreak in Germany.

Infection·2025
Same author

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.

Leukemia·2018
Same author

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Leukemia·2017
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Recent advances in oncology focus on molecular targets for "targeted therapies." Inhibitors of protein tyrosine kinases (PTKs) and monoclonal antibodies show promise in treating various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Understanding the molecular basis of cancer has led to the development of targeted therapies.
  • Signaling cascades, such as protein tyrosine kinases (PTKs), are frequently dysregulated in malignant disorders.
  • Tumor-specific cell surface proteins offer targets for antibody-based therapies.

Purpose:

  • To review the progress in identifying and targeting molecular pathways in cancer.
  • To highlight the therapeutic potential of small molecule inhibitors and monoclonal antibodies.
  • To emphasize the integration of diagnostics and therapeutics in oncology.

Summary:

  • Targeted therapies exploit molecular alterations driving cancer, including activated protein tyrosine kinases (PTKs) and tumor-specific cell surface proteins.

Related Experiment Videos

  • Small molecule inhibitors targeting PTKs have shown significant clinical responses in cancers like chronic myeloid leukemia and non-small cell lung cancer.
  • Monoclonal antibodies targeting cell surface proteins have improved outcomes in lymphomas and are being explored for other malignancies.

    • Impact:

    • Molecularly targeted therapies represent a paradigm shift in cancer treatment, moving towards personalized medicine.
    • The identification of critical molecular targets is crucial for developing effective integrated diagnostic and therapeutic strategies.
    • This approach holds the potential to significantly improve patient response rates and outcomes across various cancer types.